Within density functional theory, a variational particle number approach for rational compound design (RCD) is presented. An expression for RCD is obtained in terms of minimization of a suitably defined energy penalty functional whose gradients are the nuclear and the electronic chemical potential. Using combined quantum and molecular mechanics, a nonpeptidic anticancer drug candidate is designed.
Therefore, one tries to identify an optimal system H opt simply via O 0 O opt ‫ۋ‬ H opt . Within conventional rational drug design for instance, the interaction of a given drug candidate (H ) to a protein is often analyzed in much detail in order to know how to increase its binding affinity (O) via structural modifications. Thus, the underlying interest in a given system (H ) is usually due to its interesting properties and their potential tuning by variation of H in its chemical space.
A large variety of approaches exist that address this inversion problem, ranging from empirical-statistical quantitative structure property relationships to classical force field and semiempirical calculations [2] . The analytical expression for the potential energy in empirical force fields and the fact that the free energy is an equation of state has motivated studies connecting different molecules reversibly through a coupling parameter, commonly called . Thermodynamic integration and other approaches to relative free energies have been successfully carried out ever since Kirkwood's seminal paper in 1935 [3, 4] . However, to declare a dynamical variable in the framework of a statistical mechanics scheme and to use it for compound design has been implemented only a decade ago [5, 6] . Unfortunately, force-field approaches are intrinsically limited due to their classical and empirical nature. Specifically, they will fail to describe all those regions in chemical space where electronic structure effects occur or which have not yet been parametrized. Consequently, they do not allow one to freely explore chemical space for compound design. Using quantum mechanics, it is possible to optimize deterministically H throughout chemical space and thereby also to carry out de novo compound design in the sense of Refs. [7] [8] [9] . However, even a detailed and accurate understanding of the left-hand expression in Eq. (1) does not yet necessarily lead to an inversion of the mapping. Consequently, current applications of first principles methods are quite heuristic.
While a general inversion of the mapping of H ‫ۋ‬ O is not possible (different H 's can have a comparable property), we attempt here to recursively invert the mapping locally (local in chemical space). That is, starting from a given compound, a nonheuristic formulation for a rational compound design from first principles is presented. The scheme iteratively minimizes a penalty functional in particle space using standard density functional theory (DFT) [10 -12] within a grand-canonical ensemble (GCE) notation. For demonstration purposes the presented approach is applied to the design of a nonpeptidic inhibitor of the anticancer target human XIAP (X-chromosome linked inhibitor-of-apoptosis-proteins), which are overexpressed in cancer cells [13] [14] [15] [16] .
Within DFT and the Born-Oppenheimer approximation to the adiabatic separation of the nuclear and electronic wave function, any ground-state observable O is a functional of the electron density n. The latter is for a fixed number of electrons N e up to a constant in a one-to-one relationship to the external potential v [10] . For an unperturbed system, v is a simple functional of the nuclear charge distribution Z: vZr ÿ R dr 0 Zr 0 =jr ÿ r 0 j. In the classical point charge limit Zr Z I r ÿ R I , where Z I is the number of protons at r R I , i.e., the atomic number of atom I. Consequently, the observable O can be seen as a function of N e and as a functional of Z, OZN e .
In analogy to the variational optimization of atom centered potentials for molecular properties [17] , one can define an expression for rational compound design via a penalty functional P , which is to be minimized iteratively by gradient based variations of N e and Zr,
P ZN e penalizes deviations of OZN e from a desired reference property O 0 . Equation (2) turns rational compound design into a minimization problem in the discrete chemical space spanned by electrons and nuclei. As in all iterative minimization problems in high-dimensional spaces, analytical gradients offer a fundamental gain in efficiency with respect to screening techniques or finite differences. In this sense P =Z and @P =@N e -available from first principle -can be used within all sorts of gradient based minimization schemes like Newton's rule or conjugate gradient methods [18] .
Consider OZN e to be the GCE energy functional EZN e ; i.e., our system H is in contact with an electron and proton particle reservoir, and O 0 E 0 EZN e , then Eq. (2) reduces to the zero temperature GCE variational theorem [19] . The electronic GCE energy EZN e is obtained from the stationary principle for atoms and molecules at a fixed Z [20] : fEZN e ÿ e N e g 0, where EZN e R drnv F GC n. F GC n is the universal, only implicitly dependent on Z, GCE ground-state functional, while e is a Lagrange multiplier attached to the constraint that N e R drn and is called the electronic chemical potential [ e EZN e =nr @EZN e = @N e ]. e is of central importance in DFT and is greatly exploited within conceptual DFT [21] . After minimization of EZN e with respect to n, the total potential energy of a system can be given as a functional of Z, E tot ZN e EZN e 1=2 R drdr 0 ZrZr 0 =jr ÿ r 0 j. In analogy to the electronic chemical potential, we introduce here a nuclear chemical potential, n , which explicitly measures the tendency of the molecule to vary its nuclear structure Z. Unlike e (which corresponds to the molecular electronegativity [22] ), n is not a constant for each molecule but a function of space because variations of the ionic charge distribution are allowed everywhere in space,
Here, n 1 r; r 0 denotes the derivative nr 0 =Zr, which can be approximated within the linear response in the electronic structure nr 0 of the system being induced by a local infinitesimally small variation of the ionic charge distribution Zr ‫ۋ‬ Zr dZ: n 1 P N i1
. This perturbed density is available within CPMD [23] using the density functional perturbation module [24] and the perturbation Hamiltonian of Ref. [17] . F GC n=Zr consists of the functional derivatives of the Coulomb energy, of the Kohn-Sham expression for the kinetic energy of the electrons, and of the exchangecorrelation energy with respect to Z. However, for a discrete ionic charge distribution and within first order perturbation theory, Eq. (3) reduces simply to the electrostatic field at r,
Within first order perturbation theory the derivative of the energy with respect to changes in atomic number was already presented [25, 26] . However, here we consider the explicit molecular response upon an infinitesimal small variation of the nuclear charge distribution everywhere in space, which goes beyond the usual expression for the molecular response upon a variation in the external potential, namely E=v n. While the validity of Kohn-Sham DFT for the unphysical regime of pure electronic states involving noninteger occupation numbers is by now well established [27, 28] , fractional atomic numbers (classical point charges) are less problematic.
As an illustration, atomic potential energies EZ I N e have been computed using DFT and the BLYP functional [29] [30] [31] [32] for fractional number of particles (Fig. 1) . The derivative discontinuity at integer values of N e , as expected for the exact yet unknown exchange-correlation potential [20] , is not reproduced by the employed approximation to the exchange-correlation functional [32] . However, the typical convex shape of the isoprotonic curves is reproduced. The isoelectronic curves are concave, which is in agreement with Ref. [22] . The slope of the EZ I N e surface in Fig. 1 corresponds hence to linear combinations of n r R I and e . Note that the system is significantly more sensitive to variations of Z than of N e .
Within a GCE formalism n and e represent the respective response of a given system in contact with particle reservoirs upon variation of its electronic or its ionic structure. Higher derivatives of the electronic and nuclear chemical potentials define reactivity response functions and indices in the spirit of conceptual DFT 
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153002-2 [21] . For ground-state systems, further features of n can be established, (i) n r Þ R I is related to the proton affinity at r for the given geometry fR I g. As an illustration, a projection of n r Þ R I in the molecular plane of formic acid is presented in Fig. 1 [33] . Here, @ Z I V PP I f j g ÿ1=jr ÿ R I jerfjr ÿ R I j= 1 needs to be added to the perturbation Hamiltonian given explicitly in Ref. [17] . In this study, n r R I is hence approximated by the sum of the first order perturbations of the energy induced by infinitesimal variations f j ‫ۋ‬ j d j g and has been implemented into CPMD [23] . For an atom it was found to grasp roughly 90% of a finite difference result.
In principle, for the purpose of drug design, all relevant properties that define the druggability of a compound should be included in the penalty formalism of Eq. (2) and ab initio molecular dynamics (MD) should be carried out in order to include all finite temperature effects. However, without any loss of generality, here only the inhibitor's binding affinity is considered as observable, and an experimentally known suitable inhibitor compound is used as the initial structure. Specifically, in the case of XIAP, effective tetrapeptidic inhibitors were identified in vitro through combinatorial screening of the amino acid positions 1, 2, and 4 of the AVPI [ Fig. 2(a) ] sequence [35] . Although the resulting peptidic inhibitor ARPF [ Fig. 2(b) ] presents a high affinity (IC 50 of subnanomolar concentration), such peptidic sequences would be easily cleaved in vivo by proteases, which prohibits any druggability. To our knowledge, no nonpeptidic XIAP inhibitor has been proposed up to date, i.e., a nonpeptidic structure, H opt , is needed which maximizes as observable, O, the energy of interaction,
Here, E com represents the total potential energy of the complex of the inhibitor bound to the protein, and E prot and E inh correspond to the energies of the isolated protein and the inhibitor, respectively. We use for the corresponding penalty the gradient with respect to the nuclear charge distribution of the inhibitor (Z inh ),
For the design of a nonpeptidic inhibitor derived from ARPF only independent transmutations of the 9 second row atoms (I 1; . . . ; 9) constituting the three peptide bonds that need to be altered (Fig. 2) have been considered. Thus, the gradient reduces to variations at the positions of these atoms only, P =Z
Supposing that every atomic number can be changed only by ÿ1, 0, or 1, there are (3 9 ÿ 7) possible nonpeptidic mutants. It is hence intractable to fully screen the relevant chemical space and the penalty gradients offer here a way to guide the exploration at a first principles level of theory.
In order to follow these penalty gradients for a relevant configuration 5 ns of GROMOS96 43A1 [36] force-field based classical MD simulation of the human XIAP have been conducted in order to equilibrate the enzyme-peptide complexes for AVPI [ Fig. 2(a) ] and ARPF [ Fig. 2(b) ] [37] . For the computation of the penalty and its gradients, a snapshot of the equilibrated XIAP-ARPF complex has been chosen for an isolated cluster calculation with DFT [32] . This cluster consists out of the inhibitor and all residues of XIAP within 5 Å distance of the peptidic atoms, being saturated with hydrogen atoms. Starting from the highly potent ARPF [ Fig. 2(b) ], the 9 peptidic inhibitor atoms have been transmutated according to their alchemical potential. After one iteration a new nonpeptidic model compound [ Fig. 2(c) ] has been obtained that exhibits an enhancement of the interaction energy by roughly 50 kcal=mol. However, DFT calculations show that one step is insufficient: the structure is unstable as a monomer in gas phase. An iterative procedure following the f n R I g only for one atom per peptide bond, combined with conservation of charge (through saturation with hydrogen atoms), resulted after four steps into another stable nonpeptidic inhibitor compound, np-ARPF [ Fig. 2(d) ].
Relative to a QM-MM equilibrated wild-type AVPI-XIAP complex [38, 39] , the ARPF and np-ARPF-XIAP ( Fig. 2, right) complexes yield within QM-MM, respectively, an increase of the averaged interaction energies by ÿ18:9 and ÿ18:5 kcal=mol. Since only hydrogen atoms have been used to satisfy the valency of the modified peptide bonds, the entropic contributions to the macroscopic binding affinity for ARPF and np-ARPF are expected to be comparable; i.e., the IC 50 of the np-ARPF can likewise be expected to be in the subnanomolar range.
In conclusion, we have extended conceptual DFT by the chemical potential for nuclei, n r. We propose to call n r R I the alchemical potential: it measures the tendency of a system to transmutate a given atom I. QM-MM calculations combined with stability tests have allowed one to successfully apply the presented scheme to the rational compound design of a new nonpeptidic XIAP inhibitor with an expected binding affinity comparable to a highly potent tetrapeptidic inhibitor. Overall, the presented approach is general enough to be extended and applied to other compound design problems exploring chemical 
